X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): EB01
Therapeutic Area: Dermatology Product Name: EB01
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 03, 2021
Details:
EB01 is designed to inhibit the inflammatory process at its inception rather than after inflammation has occurred, the company believes that the drug could potentially exert a powerful anti-inflammatory effect without the safety concerns of steroids.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): EB01
Therapeutic Area: Dermatology Product Name: EB01
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: JSS Medical Research
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 09, 2021
Details:
EB01 contains a non-steroidal anti-inflammatory compound known as an sPLA2 inhibitor. Edesa reported that all 46 subjects in the first cohort have been randomized and dosed with either Edesa's EB01 topical treatment or a placebo cream.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Thykamine
Therapeutic Area: Dermatology Product Name: PUR0110
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: PurGenesis Technologies
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 18, 2021
Details:
According to the results from the study, Thykamine at 0.1% showed significant improvement in skin clearance versus placebo at all measured timelines, thereby meeting the primary endpoint. It showed a fast onset of the therapeutic effect.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
